Bank Julius Baer & Co. Ltd Zurich Sells 121,373 Shares of Thermo Fisher Scientific Inc. $TMO

Bank Julius Baer & Co. Ltd Zurich decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 27.9% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 314,213 shares of the medical research company’s stock after selling 121,373 shares during the period. Bank Julius Baer & Co. Ltd Zurich owned approximately 0.08% of Thermo Fisher Scientific worth $127,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of TMO. CBIZ Investment Advisory Services LLC grew its holdings in shares of Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock worth $28,000 after purchasing an additional 33 shares in the last quarter. Anderson Financial Strategies LLC purchased a new position in Thermo Fisher Scientific in the 1st quarter worth approximately $30,000. Keystone Global Partners LLC bought a new position in shares of Thermo Fisher Scientific in the 1st quarter worth $31,000. DiNuzzo Private Wealth Inc. raised its position in shares of Thermo Fisher Scientific by 406.7% during the 2nd quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock valued at $31,000 after buying an additional 61 shares in the last quarter. Finally, Clal Insurance Enterprises Holdings Ltd grew its position in Thermo Fisher Scientific by 450.0% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 77 shares of the medical research company’s stock worth $38,000 after acquiring an additional 63 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on TMO. Barclays lifted their price target on Thermo Fisher Scientific from $585.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, October 23rd. William Blair initiated coverage on shares of Thermo Fisher Scientific in a research note on Monday, August 18th. They set an “outperform” rating on the stock. TD Cowen upped their price objective on shares of Thermo Fisher Scientific from $612.00 to $654.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. UBS Group lifted their target price on shares of Thermo Fisher Scientific from $500.00 to $590.00 and gave the stock a “neutral” rating in a research report on Thursday, October 23rd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, October 14th. Nineteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $601.65.

Thermo Fisher Scientific Price Performance

Shares of TMO stock opened at $585.85 on Tuesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $610.97. The firm has a market cap of $220.11 billion, a P/E ratio of 33.84, a P/E/G ratio of 3.27 and a beta of 0.82. The business’s 50 day moving average price is $539.29 and its 200-day moving average price is $475.16.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. The company had revenue of $11.12 billion during the quarter, compared to analyst estimates of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The firm’s revenue was up 4.9% on a year-over-year basis. During the same quarter last year, the firm posted $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be given a $0.43 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.94%.

Thermo Fisher Scientific announced that its board has approved a stock repurchase program on Thursday, November 6th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical research company to buy up to 2.4% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board of directors believes its stock is undervalued.

Insider Buying and Selling

In other news, CAO Joseph R. Holmes sold 385 shares of the business’s stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Lisa P. Britt sold 10,225 shares of the stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $571.62, for a total transaction of $5,844,814.50. Following the completion of the transaction, the vice president owned 14,145 shares of the company’s stock, valued at approximately $8,085,564.90. The trade was a 41.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 41,845 shares of company stock worth $23,947,352 over the last quarter. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.